Lensar Inc (LNSR)

$4.065

+0.04

(+0.87%)

Market is closed - opens 7 PM, 22 May 2024

Insights on Lensar Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 12.10M → 10.58M (in $), with an average decrease of 12.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -3.92M → -2.15M (in $), with an average increase of 82.0% per quarter

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 79.7% return, outperforming this stock by 128.2%

Performance

  • $3.80
    $4.10
    $4.07
    downward going graph

    6.63%

    Downside

    Day's Volatility :7.32%

    Upside

    0.73%

    downward going graph
  • $1.80
    $5.30
    $4.07
    downward going graph

    55.77%

    Downside

    52 Weeks Volatility :66.04%

    Upside

    23.21%

    downward going graph

Returns

PeriodLensar IncIndex (Russel 2000)
3 Months
-6.98%
0.0%
6 Months
74.03%
0.0%
1 Year
44.15%
0.0%
3 Years
-49.25%
-20.1%

Highlights

Market Capitalization
45.9M
Book Value
$2.79
Earnings Per Share (EPS)
-1.1
Wall Street Target Price
8.0
Profit Margin
-27.57%
Operating Margin TTM
-26.92%
Return On Assets TTM
-12.79%
Return On Equity TTM
-28.86%
Revenue TTM
44.5M
Revenue Per Share TTM
4.0
Quarterly Revenue Growth YOY
28.299999999999997%
Gross Profit TTM
20.0M
EBITDA
-8.5M
Diluted Eps TTM
-1.1
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.01
EPS Estimate Next Year
-0.84
EPS Estimate Current Quarter
-0.28
EPS Estimate Next Quarter
-0.26

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Lensar Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 96.8%

Current $4.07
Target $8.00

Company Financials

FY19Y/Y Change
Revenue
30.5M
-
Net Income
-16.7M
-
Net Profit Margin
-54.76%
-
FY20Y/Y Change
Revenue
26.4M
↓ 13.58%
Net Income
-21.2M
↑ 26.72%
Net Profit Margin
-80.29%
↓ 25.53%
FY21Y/Y Change
Revenue
34.5M
↑ 30.62%
Net Income
-19.7M
↓ 7.22%
Net Profit Margin
-57.03%
↑ 23.26%
FY22Y/Y Change
Revenue
35.4M
↑ 2.61%
Net Income
-19.7M
↓ 0.01%
Net Profit Margin
-55.58%
↑ 1.45%
FY23Y/Y Change
Revenue
42.2M
↑ 19.25%
Net Income
-14.4M
↓ 26.81%
Net Profit Margin
-34.11%
↑ 21.47%
Q4 FY22Q/Q Change
Revenue
10.2M
↑ 32.06%
Net Income
-3.2M
↓ 18.16%
Net Profit Margin
-31.19%
↑ 19.13%
Q1 FY23Q/Q Change
Revenue
8.3M
↓ 19.35%
Net Income
-4.5M
↑ 39.74%
Net Profit Margin
-54.04%
↓ 22.85%
Q2 FY23Q/Q Change
Revenue
12.0M
↑ 45.56%
Net Income
-8.8M
↑ 96.3%
Net Profit Margin
-72.87%
↓ 18.83%
Q3 FY23Q/Q Change
Revenue
9.8M
↓ 18.46%
Net Income
2.6M
↓ 129.34%
Net Profit Margin
26.22%
↑ 99.09%
Q4 FY23Q/Q Change
Revenue
12.1M
↑ 23.58%
Net Income
-3.9M
↓ 252.88%
Net Profit Margin
-32.43%
↓ 58.65%
Q1 FY24Q/Q Change
Revenue
10.6M
↓ 12.53%
Net Income
-2.2M
↓ 45.06%
Net Profit Margin
-20.37%
↑ 12.06%
FY19Y/Y Change
Total Assets
34.5M
-
Total Liabilities
65.1M
-
FY20Y/Y Change
Total Assets
79.1M
↑ 129.09%
Total Liabilities
11.9M
↓ 81.7%
FY21Y/Y Change
Total Assets
66.5M
↓ 15.99%
Total Liabilities
11.6M
↓ 2.72%
FY22Y/Y Change
Total Assets
55.8M
↓ 15.98%
Total Liabilities
13.9M
↑ 19.63%
FY23Y/Y Change
Total Assets
69.6M
↑ 24.61%
Total Liabilities
22.4M
↑ 61.68%
Q4 FY22Q/Q Change
Total Assets
55.8M
↑ 1.9%
Total Liabilities
13.9M
↑ 13.44%
Q1 FY23Q/Q Change
Total Assets
52.0M
↓ 6.95%
Total Liabilities
12.5M
↓ 9.65%
Q2 FY23Q/Q Change
Total Assets
71.2M
↑ 37.02%
Total Liabilities
38.5M
↑ 207.48%
Q3 FY23Q/Q Change
Total Assets
70.9M
↓ 0.48%
Total Liabilities
34.5M
↓ 10.48%
Q4 FY23Q/Q Change
Total Assets
69.6M
↓ 1.79%
Total Liabilities
22.4M
↓ 34.99%
Q1 FY24Q/Q Change
Total Assets
66.1M
↓ 4.96%
Total Liabilities
20.6M
↓ 8.29%
FY18Y/Y Change
Operating Cash Flow
-1.9M
-
Investing Cash Flow
-3.9M
-
Financing Cash Flow
7.0M
-
FY19Y/Y Change
Operating Cash Flow
-12.6M
↑ 567.85%
Investing Cash Flow
-2.1M
↓ 46.33%
Financing Cash Flow
15.9M
↑ 129.32%
FY20Y/Y Change
Operating Cash Flow
-13.8M
↑ 9.55%
Investing Cash Flow
-326.0K
↓ 84.39%
Financing Cash Flow
50.0M
↑ 213.51%
FY21Y/Y Change
Operating Cash Flow
-9.0M
↓ 34.96%
Investing Cash Flow
-354.0K
↑ 8.59%
Financing Cash Flow
361.0K
↓ 99.28%
FY22Y/Y Change
Operating Cash Flow
-14.9M
↑ 65.64%
Investing Cash Flow
-115.0K
↓ 67.51%
Financing Cash Flow
-2.0M
↓ 651.8%
Q4 FY22Q/Q Change
Operating Cash Flow
-4.8M
↑ 1.21%
Investing Cash Flow
-57.0K
↑ 2750.0%
Financing Cash Flow
196.0K
↓ 116.33%
Q1 FY23Q/Q Change
Operating Cash Flow
-6.7M
↑ 40.73%
Investing Cash Flow
-8.0K
↓ 85.96%
Financing Cash Flow
19.8M
↑ 10012.76%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.1M
↓ 67.98%
Investing Cash Flow
-181.0K
↑ 2162.5%
Financing Cash Flow
19.8M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Lensar Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lensar Inc
Lensar Inc
25.08%
74.03%
44.15%
-49.25%
-54.83%
Stryker Corporation
Stryker Corporation
0.86%
12.4%
15.49%
28.53%
77.74%
Boston Scientific Corp.
Boston Scientific Corp.
11.25%
36.51%
40.96%
76.8%
100.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.89%
34.72%
1.32%
-5.35%
56.97%
Abbott Laboratories
Abbott Laboratories
-3.84%
0.25%
-4.89%
-12.22%
35.01%
Medtronic Plc
Medtronic Plc
5.71%
8.68%
-4.84%
-33.51%
-4.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lensar Inc
Lensar Inc
NA
NA
NA
-1.01
-0.29
-0.13
NA
2.79
Stryker Corporation
Stryker Corporation
37.6
37.6
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.33
63.33
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
38.77
38.77
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.15
32.15
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
26.83
26.83
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lensar Inc
Lensar Inc
Buy
$45.9M
-54.83%
NA
-27.57%
Stryker Corporation
Stryker Corporation
Buy
$125.6B
77.74%
37.6
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$110.8B
100.56%
63.33
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.4B
56.97%
38.77
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$179.5B
35.01%
32.15
13.96%
Medtronic Plc
Medtronic Plc
Buy
$112.2B
-4.04%
26.83
13.0%

Institutional Holdings

  • Park West Asset Management LLC

    9.79%
  • Dimensional Fund Advisors, Inc.

    5.77%
  • Vanguard Group Inc

    3.80%
  • Renaissance Technologies Corp

    2.76%
  • DCF Advisers, LLC

    2.11%
  • Brandes Investment Partners & Co

    1.99%

Company Information

lensar® is the leader in next-generation femtosecond laser technology for refractive cataract surgery. the lensar laser system offers cataract surgeons precision and accuracy, while optimizing overall visual outcomes. the proprietary augmented reality™, lensar’s reconstructed 3-d imaging, measurement, and guidance system, provides high-resolution ocular images in a single scan. this technology facilitates precise surgical incisions and treatment for ultimate accuracy and reliable outcomes, all in a single procedure room. the lensar laser system is the only femtosecond cataract laser built specifically for refractive cataract surgery. because it was designed from the ground up, every aspect of the laser has been purposefully designed to meet the needs of cataract surgeons. lensar, inc. is committed to revolutionizing refractive eye surgery. our success depends on talented and motivated individuals who share our passion for making a difference in patients’ lives. we are a young and vibra

Organization
Lensar Inc
Employees
130
CEO
Mr. Nicholas T. Curtis
Industry
Health Technology

FAQs